WALTHAM, Mass • 2023-12-07

BostonGene Announces Ten Presentations at the 65th American Society of Hematology Annual Meeting & Exposition

5 min to read

Presentations with Leading Institutions Reveal BostonGene’s AI-driven Molecular and Immunoprofiling Solutions as Crucial Tools for Characterizing the Microenvironment and Peripheral Blood Immune Cells in Therapeutic Response
WALTHAM, Mass, December 7, 2023 — BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of four abstracts for oral presentation, four abstracts as poster presentations, and two abstracts for online publication at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually. BostonGene will exhibit in booth #2350.

“We look forward to showcasing compelling data at ASH, which will underscore the pivotal role of molecular and immune profiling alongside advanced analytics in propelling precision medicine for individuals battling cancer, “said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Details of the presentations are below:

Oral presentations:

Abstract: 601
Title: Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up
Date & time: Sunday, December 10, 2023 | 4:30 PM
Location: Room 6CF – San Diego Convention Center
Presenter: Stephen J Schuster, MD, Abramson Cancer Center, University of Pennsylvania

This presentation highlights results from the Phase 2 ELARA trial that show efficacy, safety, pharmacokinetic, and exploratory biomarker analyses in relapsed/refractory follicular lymphoma patients treated with tisagenlecleucel after a median follow-up of more than 3 years. Higher baseline levels of CD8+ naive T cells are associated with improved long-term clinical outcomes.

Research conducted in collaboration with The University of Texas MD Anderson Cancer Center, Abramson Cancer Center, University of Pennsylvania, The University of Melbourne, Hospital Universitario, Oslo University Hospital, Royal Brisbane Hospital, University of Michigan, City of Hope National Medical Center, Moffitt Cancer Center, Hospices Civils de Lyon and Claude Bernard Lyon 1 University, Kyushu University Hospital, Tohoku University Graduate School of Medicine, University of Amsterdam, University of California San Francisco, University of Chicago, Royal Prince Alfred Hospital, Universidad de Sevilla, Oregon Health and Science University, University of Cologne, West German Cancer Center, University of Duisburg-Essen, IRCCS San Raffaele Scientific Institute, Hokkaido University, King’s College London, University of Kansas Medical Center, Ordensklinikum Linz Barmherzige Schwestern-Elisabethinen, Universitair Ziekenhuis Gent, University Hospital of Ulm, University of Bologna, Cambridge University, Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Hôpital Saint-Louis, Ludwig-Maximilians-University Hospital

Abstract: 851
Title: A CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton’s Tyrosine Kinase Inhibition
Date & time: Monday, December 11, 2023: 3:45 PM
Location: Room 6DE – San Diego Convention Center
Presenter: Alan Cooper, University of Chicago

This study highlights the discovery of a novel transcriptomic-based biomarker of BTK inhibitors (BTK-i) response in DLBCL patients. The biomarker, a CD5 gene signature, expands upon existing genetic DLBCL classifications by identifying DLBCL patients that can benefit from BTK-i, warranting further prospective validation in BTK-i clinical trials.

Research conducted in collaboration with the University of Chicago, City of Hope National Medical Center, The University of British Colombia, Janssen Research & Development, Centre for Lymphoid Cancer

Abstract: 905
Title: Machine Learning (ML)-Enabled Automation for High-Throughput Data Processing in Flow Cytometry
Date & time: Monday, December 11, 2023 | 3:45 PM
Location: Room 6CF – San Diego Convention Center
Presenter: Anna Kamysheva, MSc, BostonGene

This presentation describes BostonGene’s development of an ML-based algorithm for automated cell-type labeling that enables the detection of rare and/or new cell populations with high speed and accuracy. This algorithm is applicable in clinical settings, particularly for detecting hematological abnormalities and cancers.

Abstract: 983
Title: Addition of Acalabrutinib to Lenalidomide and Rituximab Induces High Complete Response Rates in Patients with Previously Untreated Follicular Lymphoma: Results of a Phase II Study
Date & time: Monday, December 11, 2023 | 5:30 PM
Location: Grand Hall C – Manchester Grand Hyatt San Diego
Presenter: Paolo Strati, MD, MD Anderson

The study demonstrates the safety and efficacy of lenalidomide and rituximab treatment in combination with acalabrutinib in previously untreated FL patients and highlights the use of bulk RNA sequencing with deconvolution to analyze the biological effects of this treatment combination on peripheral blood immune cells.

Research conducted in collaboration with The University of Texas MD Anderson Cancer Center

Poster presentations:

Abstract: 1676
Title: Preliminary Analysis of an Ongoing Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma
Date & time: Saturday, December 9, 2023 | 5:30 PM – 7:30 PM
Location: Halls G-H – San Diego Convention Center
Presenter: Rahul Lakhotia, MBBS, National Cancer Institute, National Institutes of Health

This study describes the preliminary analysis (including safety and efficacy) of an ongoing “window of opportunity” study of copanlisib, followed by response-adapted copanlisib and rituximab in treatment-naïve patients with follicular lymphoma (FL). Gene expression profiling was used to identify high-risk patients and find a predictive signature of response to PI3K inhibitor.

Research conducted in collaboration with the National Cancer Institute, National Institutes of Health and Mayo Clinic

Abstract: 3644
Title: A Novel Comprehensive Tumor-Informed Plasma cfDNA Assay to Monitor Minimal Residual Disease for Hematological and Solid Malignancies
Date & time: Sunday, December 10, 2023 |6:00 PM – 8:00 PM
Location: Halls G-H – San Diego Convention Center
Presenter: Anastasiya Yudina, MSc, BostonGene

This presentation describes our cell-free DNA (cfDNA) testing platform for minimal residual disease (MRD) monitoring. It encompasses all major clinically reliable genetic hotspots events and can detect clinically relevant mutations in plasma samples before clinical manifestation.

Abstract: 3001
Title: Genomic and Transcriptomic Profiles of Blastoid and Pleomorphic Mantle Cell Lymphoma Are Distinct from Classic Histology Mantle Cell Lymphoma
Date & time: Sunday, December 10, 2023 |6:00 PM – 8:00 PM
Location: Halls G-H – San Diego Convention Center
Presenter: Preetesh Jain, MD, MBBS, PhD, DM, MD Anderson

This presentation highlights the use of BostonGene’s integrated genomic and transcriptomic analysis platform to provide a comprehensive portrait of the molecular differences between blastoid and pleomorphic mantle cell lymphoma (MCL), revealing mechanistic insights that can be used for the development of more effective therapeutic strategies.

Research conducted in collaboration with The University of Texas MD Anderson Cancer Center

Abstract: 4872
Title: Long-Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells
Date & time: Monday, December 11, 2023: 6:00 PM – 8:00 PM
Location: Halls G-H – San Diego Convention Center
Presenter: Rakesh Awasthi, PhD, Novartis Institutes for BioMedical Research

This study highlights a positive association between chimeric antigen receptor (CAR) persistence in peripheral blood post tisagenlecleucel (tisa-cel) infusion and durable clinical responses across three indications.

Research conducted in collaboration with Novartis Institutes for BioMedical Research, Novartis Pharmaceuticals Corporation, Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Intermountain Primary Children’s Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Goethe University Frankfurt, University Hospital, Knight Cancer Institute, Oregon Health & Science University, Emory University School of Medicine, Medical University of Vienna, Université de Paris, Klinikum der Universität, LMU München, MD Anderson Cancer Center

Online publications:

Title: Test-the-Test: Clinical Utility of Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Lymphoma

This study shows an acceptable turn-around-time (TAT) of 8 days for the delivery of clinical reports that include clinically relevant findings and matched clinical trials, demonstrating the feasibility of using comprehensive WES and RNA-seq molecular profiling for lymphoma patients.

Research conducted in collaboration with The University of Texas MD Anderson Cancer Center

Title: Molecular Findings on Plasma Cell-Free DNA Analysis Among Adults with Histiocytic Neoplasms

This study describes the use of cell-free DNA (cfDNA) analysis to evaluate the molecular findings in adults with histiocytic neoplasms, highlighting cfDNA as a potential viable tool for discovering driver mutations in multiple cancers.

Research conducted in collaboration with The University of Alabama, Mayo Clinic

In addition to the poster presentations, the abstracts have been published online in the November supplemental issue of “Blood.”

For more information, please visit the 65th ASH Annual Meeting and Exposition website at https://www.hematology.org/meetings/annual-meeting/abstracts.

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com